Orchitis Treatments

Find Orchitis Treatments

Generic Name

Cypionate

Brand Names

Azmiro, Depo-Estradiol, Depo-Testosterone

FDA approval date: July 25, 1979

Classification: Androgen

Form: Injection, Kit

What is Azmiro (Cypionate)?

AZMIRO is indicated for testosterone replacement therapy in males in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism : testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchiectomy, Klinefelter’s syndrome, or toxic damage from alcohol or heavy metals, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone , luteinizing hormone ) above the normal range [ see Dosage and Administration.

Approved To Treat

Top Global Experts

Nannan Thirumavalavan

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

SPECTRA: Supraphysiological Androgen to Enhance Treatment Activity

Enrollment Status: Recruiting

Publish Date: July 21, 2026

Intervention Type: Procedure, Other, Drug

Study Phase: Phase 2

Summary: This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (pros...

A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

Who is this study for: Adult patients with metastatic castration-resistant prostate cancer

Enrollment Status: Recruiting

Publish Date: July 17, 2026

Intervention Type: Drug

Study Drugs: Testosterone cypionate, Enzalutamide, Testosterone enanthate

Study Phase: Phase 2

Summary: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

A Single Arm Open-label, Phase II Study of Sipuleucel-T With Bipolar Androgen Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Enrollment Status: Recruiting

Publish Date: July 01, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in th...

View All Clinical Trials